Biotech Values

[DewDiligence]

Point Biopharma goes public via reverse-merger with RACA—a SPAC sponsored by RA Capital Management:

https://www.globenewswire.com/news-release/2021/03/15/2192554/0/en/Next-generation-Radiopharmaceuticals-Company-POINT-Biopharma-to-list-on-NASDAQ-through-merger-with-Research-Alliance-Corp-I.html

POINT is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

At deal closing, the Nasdaq ticker will be changed to PNT.